GlobeNewswire Clinical StudiesOriginal article
Vascudyne’s Lab-Grown Vessel Passes the Two-Year Mark Supplying Blood to a Patient’s Heart as a Coronary Bypass
Data ReadoutpositiveLab-grown coronary bypass vesselPositive
AI Analysis
Summary
Vascudyne's lab-grown coronary bypass vessel demonstrated durability by remaining patent two years after implantation in a patient's heart, with European CABG study enrollment now complete based on data presented at EACTS 2026.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Lab-grown vessel remained patent (open) for two years post-implant in coronary bypass application
Importance:6/10
Sentiment:
0.75
regenerative_medicinecardiovascularmedical_deviceCABGEACTS_2026
Read the original article
Published by GlobeNewswire Clinical Studies on October 8, 2026 5:23 PM